Companies › Bharat Biotech International
3 active drug programs in 5 registered trials: 4 Phase 2, 1 Phase 3; Infectious disease; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ROTAVAC 5D Live attenuated rotavirus 116E vaccine | – | Phase 3 | Rotavirus Infection of Children | – |
| BBV87 Inactivated Chikungunya Virus Vaccine | – | Phase 2 | Active Immunisation for Chikungunya Virus Infection | Aug 2027 |
| MTBVAC (BBV169) Live attenuated Mycobacterium tuberculosis vaccine | MTB | Phase 2 | Tuberculosis (TB); HIV I Infection | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06200844 | ROTAVAC 5D | Phase 3 | Rotavirus Infection of Children | Infectious disease | Jan 2025 |
| NCT06997367 | MTBVAC (BBV169) | Phase 2 | Tuberculosis (TB) | Infectious disease | Sep 2025 |
| NCT07555392 | BBV87 | Phase 2 | Active Immunisation for Chikungunya Virus Infection | Infectious disease | Aug 2027 |
| NCT05947890 | MTBVAC (BBV169) | Phase 2 | HIV I Infection | Infectious disease | Nov 2027 |
| NCT06272812 | MTBVAC (BBV169) | Phase 2 | Tuberculosis (TB) | Infectious disease | Dec 2028 |
–
Sinovac Life Sciences Green Cross Bavarian Nordic Osivax Artcline
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.